# A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

> **NCT04150029** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 90 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** MBG453
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04150029
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-01
- **Primary completion:** 2024-10-25
- **Final completion:** 2024-10-25
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Novartis made a decision to early terminate the sabatolimab clinical development program, including the CMBG453C12201 trial, following the negative results from other 2 trials.
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150029, "A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04150029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*